Epigenic Therapeutics

Epigenic Therapeutics (益杰立科) is a clinical-stage biotech developing epigenetic regulation therapies for chronic diseases, built on its proprietary EPIREG™ platform, which uses DNA methylation and histone modification to durably silence target genes — a safer alternative, in the company's framing, to DNA-cutting gene editing . The company is co-founded and led by CEO Baohong Zhang, and is a Qiming Venture Partners portfolio company; it raised a $60 million Series B in 2025, with Qiming continuing to invest . Its lead asset EPI-003, an LNP-delivered epigenetic therapy for chronic hepatitis B, received FDA IND clearance in late 2025 — described as the first LNP-based epigenetic regulation therapy to enter clinical trials globally — with Phase 1 trials underway in New Zealand, Australia, and Hong Kong . More recently, in early 2026 it appointed Chloe You as CMO and Kelly Shi as CFO .